TCGC: Clinical Genome Conference TCGC: Clinical Genome ConferenceTCGC: Clinical Genome Conference

TCGC: The 4th Annual Clinical Genome Conference 2015
- TCGC:第4回臨床ゲノム年次学会 2015年 -
2015年6月22 - 24日
米国、カリフォルニア州、サンフランシスコ、ホテル カブキ

次世代シーケンシングプラットフォームの信頼性、堅牢性、再生可能性はもはや疑う余地がなく、ゲノミクスの臨床導入という止められない勢いが現実のものとなっています。しかしながら、ゲノム知識を医療の進展に成功裏に展開し臨床に活用するためには多くの課題が残されています。

Bio-IT WorldとCambridge Healthtech Instituteは、第4回目となる年次学会TCGC: The Clinical Genome Conferenceを再び開催します。当学会では、臨床ゲノミクスに影響を及ぼすステークホルダーの方々を招き、臨床ゲノム医療の応用を広げるための新たな研究結果や解決策を共有します。


アジェンダ

1日目 | 2日目 | 3日目

6月22日(月)


9:00 am ショートコースの参加登録開始とモーニングコーヒー

10:00 am-1:00 pm ショートコース


2:00 学会の参加登録開始

3:00 議長による開会の挨拶

Eric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center


基調セッション

3:15 キーホールからゲノムワンダーランドへ:常識、尋常でないナンセンスを超えて

Nathaniel PearsonNathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome Center

One hundred fifty years after Gregor Mendel first systematically probed genetic heritability, we risk forgetting a key insight from his work, in our rush to broaden clinical genomics from urgent diagnosis for a few to lifelong care for all. By fully embracing that insight now, we can wisely bolster our health infrastructure for the long haul.

4:00 ウェルネスの進化に向けた予防医学と個別化医療との原則統合

Nathan PriceNathan D. Price, Ph.D., Associate Director, Institute for Systems Biology

Future medicine will be more proactive and data-rich than anything before possible - and will focus on maintaining and enhancing wellness more than just reacting to disease. We have launched a large-scale 100K wellness project that integrates genomics, proteomics, transcriptomics, microbiomes, clinical chemistries and wearable devices to monitor wellness and disease. I will present results from our pilot study of 107 individuals, showing how this data led to actionable findings for individuals to improve health and reduce risk drivers of disease.

4:45 翻訳癌ゲノムにおけるビッグデータ

Laura J. van 't VeerLaura J. van 't Veer, Ph.D., Director, Applied Genomics and Angela and Shu Kai Chan Endowed Chair, Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Molecular genomics contributes to the knowledge of who is at risk to develop cancer, how external factors may influence this risk, whether tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. Dr. van 't Veer's current research involves integrating various types of genomics data, including next-generation sequencing big data, and is aimed at understanding the molecular basis for early response to therapy as a surrogate for long-term survival prediction.


5:30 展示会場での歓迎レセプションとポスター観賞

6:30 第1日の終了


1日目 | 2日目 | 3日目

6月23日(火)

7:00 am 朝食プレゼンテーションまたはモーニングコーヒー


ゲノミクスが誘導する癌治療

8:00 議長の挨拶

Nathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome Center


8:05 特別プレゼンテーション:CIViC:癌における異型の臨床的解釈

MalachiGriffithMalachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of Medicine

To realize the potential of personalized medicine, genomic aberrations must be placed in the context of therapeutic response and diagnostic or prognostic associations. The evidence for these associations must be captured and characterized so that we can achieve a principled consensus among genomic experts, pathologists and oncologists on how best to interpret a genomic alteration in a clinical context. To this end, we present CIViC as a forum for the clinical interpretation of variants in cancer.


8:35 非小細胞肺癌におけるDNA再配置を用いた独立した原発巣と肺内転移の同定

GeorgeVasmatzisGeorge Vasmatzis, Ph.D., Assistant Professor, Laboratory Medicine & Pathology, Mayo Clinic & Foundation

Distinguishing independent primary tumors from intrapulmonary metastases in non-small cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement-based approach to differentiate multiple primary tumors from metastasis. A total of 41 tumor samples were sequenced. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. Concordance between histology and genomic data occurred in the majority of cases. Discrepant cases were resolved by genome sequencing.

9:05 個別化乳癌予防におけるゲノムシーケンシングの役割

WeivaSiehWeiva Sieh, M.D., Ph.D., Assistant Professor, Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine

The benefits of genome sequencing for guiding personalized preventive strategies at the population level are uncertain. We evaluated the benefits and harms of targeting preventive efforts to the subpopulation of women whose genomes put them at highest risk of breast cancer using mathematical models for (1) 86 currently known breast cancer susceptibility alleles and (2) assuming complete knowledge of all breast cancer genes. Our findings suggest that genome sequencing has the potential to guide personalized breast cancer prevention, and that the benefits will improve with increased understanding of the genetic etiology of breast cancer.

9:35 内容は後日発表します

David Jackson, Ph.D., Chief Innovation Officer, Molecular Health

9:50 スポンサープレゼンテーション

10:05 展示会での休憩とポスター観賞

10:45 前立腺癌の遺伝的リスクを理解するための遺伝子データおよびエピジェネティックデータの統合

BogdanPasaniucBogdan Pasaniuc, Ph.D., Assistant Professor, Pathology & Laboratory Medicine and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles

Although genome-wide association studies have identified over 100 genetic loci that increase risk for developing prostate cancer, their functional effects on risk remain largely unknown. I present new approaches that integrate large-scale genetic data with cell-type-specific epigenetic functional annotation data to gain insights into the genetic architecture of prostate cancer risk.

11:15 ディープシーケンシングによる循環腫瘍DNAの超高感度検出

MaxDiehnMaximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford University

Circulating tumor DNA (ctDNA) represents a promising biomarker for detection and monitoring of cancers. Work on clinical applications of next-generation sequencing-based ctDNA quantitation will be discussed.


Genospace11:45 内容は後日発表します。

12:15 pm 休憩

12:30 昼食プレゼンテーションまたは各自での昼食


“ウェルネス”の理解

2:00 議長の挨拶

Malachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of Medicine

2:05 障害の健康資源としての全ゲノムシーケンスへのアプローチ

SekWonKongSek Won Kong, M.D., Assistant Professor, Medicine/Informatics Program, Harvard Medical School and Boston Children's Hospital

Accumulated genomic variants provide a foundation of information in the context of precision medicine, and an individual genome can be a resource for lifelong well being. To achieve analytical validity of whole-genome sequence for clinical use, a reproducible and accurate analysis and interpretation pipeline is required. Carrier status of disease-causing mutations and pharmacogenomic variants are of primary interest; however, estimating genetic liability for complex diseases using established risk alleles might be informative. We demonstrate how complex trait risk variants from an individual genome can be summarized and reported for the general clinician and patients.

2:35 世界最高齢者らの全ゲノムシーケンシング

KristenFortneyKristen Fortney, Ph.D., Research Scientist, Stuart K. Kim Laboratory, Developmental Biology, Stanford University

Supercentenarians (110 years or older) are the world's oldest people. We sequenced the genomes of 17 supercentenarians to see if we could uncover the genetic basis for their extreme longevity. From this small sample size, we were unable to find rare protein-altering variants significantly associated with extreme longevity. We have made the complete genomes of all 17 supercentenarians available as a resource to assist discovery in future studies.

3:05 スポンサープレゼンテーション

3:35 展示会場での休憩とポスター観賞

4:15 臨床サンプルにおけるディープメタゲノミクスシーケンシングの理解

ArunRawatArun Rawat, Ph.D., Bioinformatician II, Translational Genomics Research Institute

Decreasing cost of next-generation sequencing provides unique opportunities to identify host-associated microbial communities in clinical samples. Our goal is to understand the unknown etiologic agent in symptomatic patients to allow faster clinical decisions. Prediction of undiagnosed disease is possible with high reliability despite the variability in metagenomic samples and computational challenges.

4:45 個人の健康を増進するための生殖細胞ゲノミクスの活用

JohnWitteJohn S. Witte, Ph.D., Professor, Epidemiology & Biostatistics and Urology; Head, Division of Genetic and Cancer Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader, Cancer Center Program in Cancer Genetics, University of California, San Francisco



5:15 双方向グループ討論会

Wrap up the day with a moderated discussion group to brainstorm the translation of genomic technologies into the clinic. Use this opportunity to share new findings, propose solutions and develop collaborations with the diverse stakeholders advancing genomic medicine.

6:00 第2日の終了


1日目 | 2日目 | 3日目

6月24日(水)

7:00 am 朝食プレゼンテーションまたはモーニングコーヒー


臨床シーケンシング:適切な投資となるか

8:00 議長の挨拶

Katherine Tynan, Ph.D., Business Development & Strategic Consulting for Diagnostics Companies, Tynan Consulting LLC

8:05 次世代ゲノムシーケンシングから付随的研究結果を回収する際の費用対効果の評価

CarolineBennetteCaroline Bennette, MPH, Ph.D., K12 Patient-Centered Outcomes Research Scholar, Group Health Research Institute, University of Washington

Our team at the University of Washington recently developed a decision-analytic policy model to evaluate the potential clinical and economic impact of returning ACMG-recommended incidental findings from next-generation sequencing. We found that returning incidental findings is likely cost effective for certain patient populations receiving next-generation sequencing, but that screening of generally healthy individuals is likely not cost effective based on current data and sequencing costs. We describe the development of our policy model, summarize key findings and discuss future research directions.

8:35 大規模小児病院におけるゲノム/精密医療に関するケーススタディとケースシリーズ

StephenKingsmoreStephen F. Kingsmore, MB, ChB, BAO, D.Sc., FRCPath, Executive Director, Panomic Medicine, Children's Mercy - Kansas City

Over 5400 single-gene diseases are known, affecting 4-8% of children. Genome and exome sequencing are starting to change the approach to patient management in these diseases, specifically regarding early etiologic diagnosis and "N-of-1-genome" treatment strategies. Six large retrospective case studies have been or soon will be published providing the first measurements of costs and benefits of genomic/precision medicine in neurodevelopmental disorders and acutely ill infants. Two individual patient cases illustrate the transformative potential of genomic/precision medicine.

9:05 閉塞性冠動脈疾患の症状を有する患者の評価:年齢、性別、遺伝子発現を組み込んだ血液試験の臨床的有効性、臨床利用性、経済的利用性

MarkMonaneMark Monane, M.D., CMO, CardioDx

Patients with symptoms suggestive of obstructive coronary artery disease (CAD) frequently undergo unnecessary testing and procedures. Approximately $6.7 billion/year is spent on non-invasive and invasive testing in the U.S. in the non-diabetic population with no prior revascularization or myocardial infarction, yet some patients continue to be misdiagnosed. We present data on a blood test for use in the evaluation of obstructive CAD among symptomatic patients. Data of clinical validity (96% NPV), clinical utility (multiple change behavior studies) and economic utility (cost implications) will be presented.

9:35 スポンサープレゼンテーション

10:05 展示会場での休憩とポスター観賞

10:45 臨床ゲノミクスにおける神話と現実

DavidMoskowitzDavid W. Moskowitz, M.D., Chairman, CEO, CMO & CSO, GenoMed, Inc.

Much of what passes for clinical genomics has been a waste of time and money, guided by unrealistic clinical paradigms. This has been fine, because the healthcare system is fundamentally anti-innovative, and is happy to waste the public's time and money. But for anybody who wants to capture marketshare, it is helpful to review what does and doesn't work.

11:15 パネル討論会:医療ビジネスモデル変換の時代におけるゲノムシーケンシングサービスの償還

At a time when payers are asking themselves, "Why pay for sequencing services?" come meet the people who are successfully crafting reimbursement arguments for the payers in disease areas as diverse as inherited genetic diseases and oncology. Find out the tactics that are working and why.

Moderator:
KatherineTynanKatherine Tynan, Ph.D., Tynan Consulting LLC





Panelists:


StephenKingsmoreStephen F. Kingsmore, MB, ChB, BAO, D.Sc., Children's Mercy - Kansas City






DavidMoskowitzDavid W. Moskowitz, M.D., GenoMed, Inc.






Additional Panelists to be Announced




12:00 pm 休憩

12:15 昼食プレゼンテーションまたは各自での昼食


医療のためのビッグデータ解析

1:30 議長の挨拶

John E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser Permanente


1:35 特別プレゼンテーション:データ分析による医療への影響 − 創薬、ゲノミクス、およびウェアラブルにおける見通し

SomaleeDattaSomalee Datta, Ph.D., Director, Bioinformatics, Stanford Center for Genomics & Personalized Medicine, Stanford University School of Medicine

In healthcare, we have an ever-increasing pile of data (aka, Data Tsunami, our favorite cliché). In the last two decades, we have also made tremendous strides in our computational bandwidth. We even found Higgs! What are the challenges with our healthcare data given the existing computational bandwidth?


2:05 中国における潜在的臨床ゲノミクスの応用

Bill Zheng, Ph.D., Director, Bioinformatics Section, Institute of Genetic Engineering, Southern Medical University

Next-generation sequencing and microarrays are being extended to clinical diagnosis. Disease can be diagnosed more efficiently and effectively, and the Chinese market has huge innovations in translational medicine. We present the marketing expansion in clinical medicine as well as in health management in China, plus developments in data mining and data management.

2:35 スポンサープレゼンテーション

3:05 展示会場での休憩とポスター観賞

3:45 PatientsLikeMe:患者報告データのためのソーシャルネットワークと研究プラットフォーム

MarciaNizzariMarcia M. Nizzari, MS, Vice President, Engineering, PatientsLikeMe, Inc.

With over 300,000 users, 2,300 conditions and 25 million+ medical datapoints collected, PatientsLikeMe provides a rich source of patient-reported phenotypic data. Patient-reported data provide key input into many areas of healthcare; clinical, payer, pharmaceutical and outcomes research will be positively disrupted by this new source of valuable information. This talk covers existing and proposed uses of those data to drive insights through integration with EHR, NGS data and other sources of -omics data.


4:15 特別プレゼンテーション:癌のビッグデータ分析におけるONCOSCAPEの応用

EricHollandEric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center

We have developed a tool for visualization of combined clinical/molecular data for cancer patients. This tool has been used to interrogate multiple public and private datasets for molecular contributions to clinical behavior.


4:45 パネル討論会:分析学と現実:健康と疾患における遺伝子と現象子との間の境界線の不鮮明さ:オントロジーへの影響と着陸遅滞

To maximize the clinical utility of genomic sequencing data, clinicians must ensure that both genomic and phenomic data is successfully integrated into the electronic health record (EHR) and other patient-centered platforms. This in turn requires understanding of technical infrastructure, security issues, policy requirements and the nature of the data itself. Learn about these topics and more from this panel of experts.

Panelists:

BeckySwainBecky Swain, Entrepreneur & Founding Member, Cloud Security Alliance






JohnMattisonJohn E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser Permanente





Additional Panelists to be Announced



5:30 学会の終了



1日目 | 2日目 | 3日目

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

» スポンサー

» メディアパートナー


Catalog

イベントカレンダー
医薬品関連の国際会議

医薬品関連の国際会議

メール配信サービス
メール配信サービス

関連会議のご案内をご希望の方はこちら